Is Pharmeasy an Unicorn?

PharmEasy (API Holdings) FAQs No Comments

Yes, Pharmeasy is an Unicorn. The Mumbai headquartered API holdings, the parent company of Pharmeasy entered the unicorn club after raising funding of $350 million form Prosus Ventures and TPG growth at the valuation of $1.5 billion in 2021. The current valuation i.e. as on 25.07.2022, of Pharmeasy is $4billion. The company has already filed DRHP with SEBI and got approval for its IPO and aiming the valuation around $7-8 billion. The company has acquired many businesses like Aknamed, its rival Medlife, and Thyrocare which is a listed company.

Please Note:

Unicorn means the company which has achieved a valuation of $1billion or Rs.7000 Crores (1$=Rs.70)

Valuation formula = No. of Shares * Market Price

If you check the balance sheet of Pharmeasy you will see that they have ~610 Crores shares and the current market price of Pharmeasy in the unlisted market is Rs.50 per share.

Valuation would be 50*610 = Rs.30,500 Crores. As you can see the valuation is above Rs.7000 Crores, so it is an Unicorn.

0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments